Even when a drug manufacturer is able and willing to make an investigational therapy available through expanded access, the success of such programs may hinge on the clinical community's response, as well as logistical and financial considerations.
Tammy Phinney, vice president of regulatory affairs at Biogen Inc., shared the company's experience with one expanded access program (EAP) at an April 16 meeting on clinical trial inclusion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?